Bet_Noire/iStock through Getty Photos
Though the second quarter and first half of 2022 had been robust for a lot of firms within the biopharma area, many buyers are on the lookout for a turnaround within the second half of the 12 months.
A complete of 16 new therapies were approved within the first half of the 12 months. Primarily based on latest annual traits, that is a bit paltry given the U.S. FDA permitted 50 new therapies in 2021 and 53 in 2020.
A number of firms are poised for a lift because of FDA motion (PDUFA) dates which can be upcoming.
Listed here are 5 candidates that the FDA is scheduled to decide on in H2 which can be essentially the most anticipated — and will affect the corporate’s inventory worth.
1. Bristol-Myers Squibb and deucravacitinib.
Bristol (NYSE:BMY) has loved a affluent first half of the 12 months with shares up 24%. A Sept. 10 PDUFA date for deucravacitinib for moderate-to-severe plaque psoriasis may add upside.
As a allosteric tyrosine kinase 2 inhibitor, deucravacitinib is a possible first-in-class remedy. It’s seen as a competitor to Amgen’s Otezla (apremilast). Bristol (BMY) has projected peak gross sales of deucravacitinib of $4B.
BMY already has two approvals this 12 months: Opdualag (nivolumab and relatlimab) for melanoma and Camzyos (mavacamten) obstructive hypertrophic cardiomyopathy. The corporate gained the latter drug by way of its 2020 acquisition of MyoCardia.
2. bluebird bio and beti-cel and eli-cel.
Bluebird (NASDAQ:BLUE) could possibly be singing glad notes in August and September if the FDA approves these lentiviral vector (LVV)-based gene therapies. The motion dates for beti-cel and eli-cel are, respectively, Aug. 19 and Sept. 16.
Prospects are good for approval after an FDA panel backed both therapies in June.
Beti-cel is for β-thalassemia, a uncommon blood dysfunction, whereas eli-cel is for the uncommon neurodegenerative dysfunction cerebral adrenoleukodystrophy.
The therapies may have peak sales of $100M each, in keeping with Edmund Ingham, a Searching for Alpha contributor.
3. Novartis/BeiGene and tislelizumab.
Novartis (NYSE:NVS) has rather a lot on the road for tislelizumab for esophageal squamous cell carcinoma. That is as a result of the Swiss pharma doled out $650M upfront and up $1.55M in milestone payments in 2021 to Beigene (BGNE) for ex-China rights to the anti-PD-1 antibody.
In H1 2022, Novartis (NVS) shares stagnated, falling ~3.5%. However with Morgan Stanley Matthew Harrison saying final 12 months that tislelizumab may usher in at the least $2B in revenues yearly, the July 12 motion date may change Novartis’ (NVS) fortunes.
4. Amylyx Prescription drugs and AMX0035.
AMX0035 is a mix of auroursodeoxycholic acid and sodium phenylbutyrate, two compoundss that shield nerve cells from harm. The drug is believed to ease endoplasmic reticulum stress and mitochondrial dysfunction.
In early June, the FDA knowledgeable Amylyx (NASDAQ:AMLX) it was extending the PDUFA date for the amyotrophic lateral sclerosis (ALS) treatment to Sept. 29.
In March, an FDA advisory panel voted 6-4 in opposition to recommending approval of the candidate. Nonetheless, in June, Health Canada approved the medicine under the name Albrioza.
The worldwide ALS market may attain $1.04 billion by 2029, per GlobalData.
5. Amicus Therapeutics and cipaglucosidase alfa and miglustat.
Amicus (FOLD) is in search of approval of the candidates as a part of a mix remedy, often known as AT-GAA, for Pompe illness. Miglustat is already permitted underneath the title Zavesca for Gaucher illness, however Amicus submitted an NDA for it for the Pompe indication.
The PDUFA dates for cipaglucosidase alfa and miglustat are, respectively, Oct. 29 and Aug. 29, following FDA extensions.
AT-GAA would seemingly compete in opposition to Sanofi’s (SNY) Lumizyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa-ngpt). Amicus has projected $1.1B in peak gross sales potential for AT-GAA.
